Columbia University Medical Center, New York, USA.
Drexel Dornsife School of Public Health, Philadelphia, USA.
Respir Med. 2022 May;196:106805. doi: 10.1016/j.rmed.2022.106805. Epub 2022 Mar 12.
Depression in patients with Chronic Obstructive Pulmonary Disease (COPD) has been shown to be chronic and potentially increase the burden of symptoms. Selective serotonin reuptake inhibitors (SSRIs) have anti-inflammatory and serotonergic effects that may improve lung function. We hypothesized that participants taking SSRIs have better lung function than those not taking SSRIs. The dataset was the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. Use of SSRIs was assessed by medication inventory; spirometry was conducted following standard guidelines; dyspnea ratings were self-reported.
Contrary to our hypothesis, FEV1 was lower, and odds of dyspnea were higher among participants taking SSRIs as compared with those not taking an antidepressant; these differences persisted even with control for potential confounders including depressive symptoms. We found no evidence of a beneficial association between SSRI use and lung function or dyspnea in a large US-based cohort.
慢性阻塞性肺疾病（COPD）患者的抑郁已被证明是慢性的，并可能增加症状负担。选择性 5-羟色胺再摄取抑制剂（SSRIs）具有抗炎和 5-羟色胺能作用，可能改善肺功能。我们假设服用 SSRIs 的参与者的肺功能比不服用 SSRIs 的参与者好。该数据集为动脉粥样硬化多民族研究（MESA）肺研究。通过药物清单评估 SSRIs 的使用情况；按照标准指南进行肺活量测定；呼吸困难评分采用自我报告。
与我们的假设相反，与不服用抗抑郁药的参与者相比，服用 SSRIs 的参与者的 FEV1 较低，呼吸困难的几率更高；即使控制了包括抑郁症状在内的潜在混杂因素，这些差异仍然存在。我们在一个大型的美国队列中没有发现 SSRI 使用与肺功能或呼吸困难之间存在有益关联的证据。
